Neurotoxicity of commonly used antineoplastic agents (first of two parts).
about
Leukoencephalopathy due to oral methotrexateOptic neuroretinitis in association with BCNU and procarbazine therapyAnticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts)Cerebrospinal fluid enolase isoenzymes and neurotoxicity in early treatment of lymphoblastic leukaemia.Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adultsGlutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancerNeuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature.Ophthalmic Metastasis of Breast Cancer and Ocular Side Effects from Breast Cancer Treatment and Management: Mini ReviewMethotrexate-induced chemical meningitis in patients with acute lymphoblastic leukemia/lymphoma.Posaconazole-vincristine coadministration triggers seizure in a young female adult: a case report.5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.Cerebral demyelination with 5-fluorouracil and levamisole.Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.Subacute leucoencephalopathy induced by carmofur, a 5-fluorouracil derivative.Lumbar puncture. Technique, indications, and complications.The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism.Neuromuscular disorders in systemic malignancy and its treatment.Folinic acid rescue for vincristine toxicity.Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report.Craniocerebral involvement in lymphoma.A comparative study of carrier detection in haemophilia A by linear discriminant function.Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).Acute encephalopathy during induction therapy for acute lymphoblastic leukemia.Accidental intrathecal vincristine administration. Report of a case.High-dose thiotepa-related neurotoxicity and the role of tramadol in children.Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?
P2860
Q28299271-EB9D818F-6AEE-4DA7-BCE5-0453CB72A5A9Q28331637-44820877-1592-4403-BE81-F27782242A60Q33974943-D8748127-8132-47B6-AF17-F1AAD1D40287Q35117902-7D810320-4B6B-4536-AD55-E18A6A0492CDQ35164117-7675DCAB-56AA-46ED-A1EA-78902C03EDD4Q35513996-32563943-23B4-4BDB-8C6E-BB46CE7C61A2Q35635738-5C2CB270-E176-4DE7-90F1-5F3DD974769AQ35640600-B517A26A-36DA-4C88-8836-7A4FCEC3E40DQ35651856-83DD56ED-1939-4EC1-A9EA-654832CBC8BEQ36169437-01EAD04A-EE11-4514-875A-31706B696B0AQ36467110-3E447D88-E477-4E10-A56C-05948205D568Q36548685-FBD1023D-AF4B-4227-AEC2-35EF1F970E40Q36734421-70284FC3-3F6D-483C-9C50-578F8C6D8D47Q37428802-37AEE087-B683-4621-9851-DCD54BC58C99Q39670386-0402B031-323F-4677-B896-08F44731B71CQ39734528-050DC4E4-AB50-4AD0-A502-D5DA9B9BAB7FQ40204282-344A18F4-0EEA-4614-B5FE-8CAB54B13AAAQ40526996-B9015E78-6121-431E-84F6-5289195639CDQ40708668-1D4E746A-F020-4504-BD3B-006129AC87DCQ42556604-E9514F32-42AE-4785-A101-DD7A371674F1Q44107912-B9D31ED8-8C1B-450A-B72A-C53560075154Q45864432-23C74A4B-25C5-4DF9-BF8E-9171F68CCC33Q45879438-32F6A4E4-841C-45D4-A00E-CA8E0F47D46FQ48410622-3A6D2E04-489B-4FD2-91F1-D219C92F5D6BQ49115556-8327C7D3-B764-45ED-B8ED-070CE478ED31Q50046503-A473B6D8-F1CA-4562-93AC-1DCEFC6F6F6FQ56520646-6CAAF47E-8364-44A0-8735-F1A4C387C10D
P2860
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
description
1974 nî lūn-bûn
@nan
1974年の論文
@ja
1974年論文
@yue
1974年論文
@zh-hant
1974年論文
@zh-hk
1974年論文
@zh-mo
1974年論文
@zh-tw
1974年论文
@wuu
1974年论文
@zh
1974年论文
@zh-cn
name
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
@en
Neurotoxicity of commonly used antineoplastic agents
@nl
type
label
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
@en
Neurotoxicity of commonly used antineoplastic agents
@nl
prefLabel
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
@en
Neurotoxicity of commonly used antineoplastic agents
@nl
P2093
P1476
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
@en
P2093
M D Walker
P H Wiernik
P356
10.1056/NEJM197407112910205
P407
P577
1974-06-01T00:00:00Z